Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426296 | 0.80 | ALDH1A1 (0.66) | KMT2AMAPTLMNAMITFALDH1A1 | |
| SCHEMBL20838602 | 0.80 | ALDH1A1 (0.66) | KMT2AMAPTLMNAMITFALDH1A1 | |
| SCHEMBL9572754 | 0.78 | KCNH2 (0.59) | KCNH2KMT2AMAPTLMNAMITF | |
| SCHEMBL8355113 | 0.78 | KMT2A (0.63) | KCNH2KMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL13114466 | 0.77 | KDM4E (0.64) | KCNH2KMT2AMAPTLMNAMITF | |
| SCHEMBL6590142 | 0.76 | MAPT (0.51) | KCNH2KMT2AMAPTLMNAMITF | |
| SCHEMBL4419843 | 0.76 | KMT2A (0.50) | KCNH2KMT2AMAPTLMNAMITF | |
| SCHEMBL7386302 | 0.75 | OXER1 (0.43) | KCNH2KMT2AMAPTLMNAMITF | |
| SCHEMBL8356629 | 0.74 | NR4A2 (0.64) | KMT2ALMNAALDH1A1MEN1KDM4E | |
| SCHEMBL13415459 | 0.74 | NR4A2 (0.64) | KCNH2KMT2AMAPTKDM4ECACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| EP-1937663-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063065-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | PPARG, PPARD, PPARA | KCNH2 2465/4885KMT2A 3191/4885MAPT 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.